FI112080B - 2-(2-amino-1,6-dihydro-6-oksopurin-9-yyli)metoksi-3-hydroksi-1-propanyyli-L-valinaatti - Google Patents

2-(2-amino-1,6-dihydro-6-oksopurin-9-yyli)metoksi-3-hydroksi-1-propanyyli-L-valinaatti Download PDF

Info

Publication number
FI112080B
FI112080B FI953592A FI953592A FI112080B FI 112080 B FI112080 B FI 112080B FI 953592 A FI953592 A FI 953592A FI 953592 A FI953592 A FI 953592A FI 112080 B FI112080 B FI 112080B
Authority
FI
Finland
Prior art keywords
amino
methoxy
dihydro
compound
oxopurin
Prior art date
Application number
FI953592A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI953592A (fi
FI953592A0 (fi
Inventor
John J Nestor
Scott W Womble
Hans Maag
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23079211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI112080(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of FI953592A0 publication Critical patent/FI953592A0/fi
Publication of FI953592A publication Critical patent/FI953592A/fi
Application granted granted Critical
Publication of FI112080B publication Critical patent/FI112080B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
FI953592A 1994-07-28 1995-07-27 2-(2-amino-1,6-dihydro-6-oksopurin-9-yyli)metoksi-3-hydroksi-1-propanyyli-L-valinaatti FI112080B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28189394A 1994-07-28 1994-07-28
US28189394 1994-07-28

Publications (3)

Publication Number Publication Date
FI953592A0 FI953592A0 (fi) 1995-07-27
FI953592A FI953592A (fi) 1996-01-29
FI112080B true FI112080B (fi) 2003-10-31

Family

ID=23079211

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953592A FI112080B (fi) 1994-07-28 1995-07-27 2-(2-amino-1,6-dihydro-6-oksopurin-9-yyli)metoksi-3-hydroksi-1-propanyyli-L-valinaatti

Country Status (33)

Country Link
EP (1) EP0694547B1 (es)
JP (1) JP3090305B2 (es)
KR (1) KR100358626B1 (es)
CN (1) CN1045089C (es)
AT (1) ATE179173T1 (es)
AU (1) AU697107B2 (es)
BR (1) BR9503468A (es)
CA (1) CA2154721C (es)
CO (1) CO4410181A1 (es)
CY (2) CY2180B1 (es)
CZ (1) CZ290511B6 (es)
DE (3) DE69509173T2 (es)
DK (1) DK0694547T3 (es)
ES (1) ES2083348T3 (es)
FI (1) FI112080B (es)
GR (2) GR960300021T1 (es)
HK (1) HK1012339A1 (es)
HU (1) HU216867B (es)
IL (1) IL114735A (es)
LU (1) LU91136I2 (es)
MA (1) MA23631A1 (es)
MY (1) MY114393A (es)
NL (1) NL300071I2 (es)
NO (2) NO312899B1 (es)
NZ (1) NZ272652A (es)
PE (1) PE32296A1 (es)
PL (1) PL180609B1 (es)
RU (1) RU2133749C1 (es)
SA (1) SA95160158B1 (es)
TR (1) TR199500895A2 (es)
TW (1) TW434242B (es)
UY (1) UY24006A1 (es)
ZA (1) ZA956228B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
AU1592897A (en) * 1996-01-26 1997-08-20 F. Hoffmann-La Roche Ag Process for preparing purine derivatives
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5700936A (en) * 1996-01-26 1997-12-23 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol valinate
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
CN1064683C (zh) * 1996-01-26 2001-04-18 弗·哈夫曼-拉罗切有限公司 制备嘌呤衍生物的方法
US5869493A (en) * 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
US6703394B2 (en) 1996-02-16 2004-03-09 Medivir Ab Acyclic nucleoside derivatives
US6184376B1 (en) 1997-02-10 2001-02-06 Mediver Ab Synthesis of acyclic nucleoside derivatives
CA2277151C (en) * 1997-02-10 2007-04-17 Medivir Ab Synthesis of acyclic nucleoside derivatives
SG96604A1 (en) * 1997-08-15 2003-06-16 Medivir Ab Nucleosides analogues, such as antivirals including inhibitors of retroviral reverse transcriptase and the dna polymerase of hepatitis b virus (hbv)
AU1711599A (en) * 1997-12-19 1999-07-12 Bristol-Myers Squibb Company Prodrugs of lobucavir and methods of use
WO1999051613A1 (en) * 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
KR20030015655A (ko) * 2001-08-17 2003-02-25 한미약품공업 주식회사 항암제의 경구흡수율을 증가시키는 인단계 화합물의결정성 산부가염, 이의 제조방법 및 이를 함유하는 약학적조성물
ES2330628T3 (es) * 2002-04-23 2009-12-14 Aventis Pharmaceuticals Inc. Ester del acido 3-(amino sustituido)-1h-indol-2-carboxilico y derivados del ester del acido 3-(amino sustituido)-benzo(b)tiofeno-2-carboxilico como imhibidores de expresion del gen de interleucina-4.
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
AU2004206827A1 (en) 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
CA2537132A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Amorphous valganciclovir hydrochloride
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
AU2005269753B2 (en) * 2004-07-19 2011-08-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
ZA200702234B (en) * 2006-03-21 2008-07-30 Cipla Ltd Preparation of ester of purine derivatives
US8173158B2 (en) 2007-10-12 2012-05-08 Takeda Pharmaceuticals U.S.A., Inc. Methods of treating gastrointestinal disorders independent of the intake of food
CN103562207B (zh) * 2011-05-31 2016-08-17 法尔玛赞公司 用于制备缬更昔洛韦的2-氨基-9-((2-苯基-1，3-二噁烷-5-基氧基)甲基)-1h-嘌呤-6(9h)-酮化合物的制备方法
KR102312533B1 (ko) 2021-02-24 2021-10-15 주식회사 이웅 자동 스패너

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8202626A (nl) * 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
IE842642L (en) * 1983-10-31 1985-04-30 Harvard College Purine Derivatives
KR910000198B1 (ko) * 1984-12-12 1991-01-23 신텍스(유.에스.에이.) 인코포레이티드 글리세롤의 알콕시메틸 에테르 및 알콕시메틸 에스테르의 제조방법
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
CA2005815C (en) * 1988-12-19 1999-08-03 Wellcome Foundation Limited (The) Antiviral acyclic nucleoside derivatives

Also Published As

Publication number Publication date
AU2719595A (en) 1996-02-08
JP3090305B2 (ja) 2000-09-18
HK1012339A1 (en) 1999-07-30
NL300071I1 (nl) 2002-02-01
MY114393A (en) 2002-10-31
NO312899B1 (no) 2002-07-15
DE10299032I2 (de) 2006-06-14
JPH0841061A (ja) 1996-02-13
RU2133749C1 (ru) 1999-07-27
CA2154721A1 (en) 1996-01-29
NO2003001I2 (no) 2007-06-11
GR960300021T1 (en) 1996-04-30
NL300071I2 (nl) 2002-03-01
TW434242B (en) 2001-05-16
PL180609B1 (pl) 2001-03-30
TR199500895A2 (tr) 1996-06-21
PE32296A1 (es) 1996-08-07
CY2004003I1 (el) 2009-11-04
CZ193995A3 (en) 1996-02-14
CO4410181A1 (es) 1997-01-09
CY2004003I2 (el) 2009-11-04
ES2083348T3 (es) 1999-08-01
FI953592A (fi) 1996-01-29
ZA956228B (en) 1996-02-22
BR9503468A (pt) 1996-02-27
NO952977D0 (no) 1995-07-27
DE694547T1 (de) 1996-10-24
DE69509173D1 (de) 1999-05-27
PL309812A1 (en) 1996-02-05
IL114735A0 (en) 1995-11-27
EP0694547B1 (en) 1999-04-21
AU697107B2 (en) 1998-09-24
EP0694547A3 (en) 1996-06-05
LU91136I2 (fr) 2005-07-06
NZ272652A (en) 1996-12-20
MA23631A1 (fr) 1996-04-01
CZ290511B6 (cs) 2002-08-14
EP0694547A2 (en) 1996-01-31
ES2083348T1 (es) 1996-04-16
GR3030678T3 (en) 1999-11-30
IL114735A (en) 1998-06-15
HU9502238D0 (en) 1995-09-28
NO952977L (no) 1996-01-29
RU95113148A (ru) 1997-06-27
CA2154721C (en) 2001-01-02
HU216867B (hu) 1999-09-28
KR100358626B1 (ko) 2003-01-14
ATE179173T1 (de) 1999-05-15
CN1122804A (zh) 1996-05-22
DE69509173T2 (de) 1999-10-21
CY2180B1 (en) 2002-08-23
DE10299032I1 (de) 2003-01-23
SA95160158B1 (ar) 2006-05-20
HUT73246A (en) 1996-07-29
DK0694547T3 (da) 2000-01-03
KR960004345A (ko) 1996-02-23
UY24006A1 (es) 2001-07-31
FI953592A0 (fi) 1995-07-27
CN1045089C (zh) 1999-09-15

Similar Documents

Publication Publication Date Title
FI112080B (fi) 2-(2-amino-1,6-dihydro-6-oksopurin-9-yyli)metoksi-3-hydroksi-1-propanyyli-L-valinaatti
US6083953A (en) 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative
JP7367908B2 (ja) 標的タンパク質分解化合物、その抗腫瘍応用、その中間体および中間体の応用
FI89713B (fi) Foerfarande foer framstaellning av terapeutiskt aktivt 2-(2-amino-1,6-dihydro-6-oxo-9h(purin-9-yl)metoxi)etyl-l-valinat eller l-isoleucinat eller deras salt
US9315523B2 (en) Cyclic dinucleosides
US5543414A (en) Achiral amino acid acyl esters of ganciclovir and its derivatives
EP3919488A1 (en) Immunomodulator
WO1997027196A1 (en) Process for preparing purine derivatives
EP2865669B1 (en) Novel rebamipide prodrug, method for producing same, and usage thereof
KR19990076616A (ko) 2,7-치환된 옥타하이드로-피롤로[1,2-에이]피라진 유도체
ES2180923T5 (es) Proceso para la preparacion de derivados de purina.
ES2641190T3 (es) Procedimiento de síntesis de IB-MECA
EP1891071B1 (en) Cyclopropanecarboxylate esters of acyclovir
TW202339766A (zh) 非環狀硫醇前藥
KR100290533B1 (ko) 항바이러스 활성을 가지는 2-아미노퓨린

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20040001

SPCE Application for extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: L20040001

MA Patent expired
SPCP Extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: 241

Extension date: 20170320